Dan Chen
@DanChenMDPhD
Co-author of the cancer-immunity cycle and the immune set point with Ira Mellman; Opinions are my own.
Continued support for the importance of PDL1 pathway inhibition combined with VEGF blockade. An interesting Venn diagram for non-overlapping but related biology between #cancer #immunotherapy and #angiogenesis. Positive trials now in #NSCLC #HCC #RCC #ProstateCancer #endometrial
💫🌟Fantastic talk with the usual clarity!!!👏👏👏 🔬 🔝🔝🔝#CONTACT-2 Phase 3 Study Results are in! Combining cabozantinib & atezolizumab shows promise for mCRPC. By @neerajaiims 🎯 Highlights: mCRPC with prior NHT failure, extrapelvic nodal or visceral metastasis. 📊 Key…
We all know it's tough out there in @biotech land. Down rounds, IPO window shut, Trumpster fires, all of that. But the startups keep coming and there are great people with great science doing great things. We celebrate that every year with the Endpoints 11, and we'd like to hear…
discussant slides on $SMMT #Akeso ivonescimab / $BNTX #Biotheus BNT327 - PM8002 in TNBC, ESG401 TROP2 ADC in HR+/HER2- & TNBC #ESMO24 3/x @DanChenMDPhD yuo have another fork of your cancer immunity cycle, via @CarmenCriscit, incorporating the role of VEGF (& pot. synergy w/ IO)
Genentech, a biotech with a storied past, confronts new turbulence in the present. My story for @statnews, based on interviews with former & current employees as well as industry observers statnews.com/2024/09/16/gen…
Neoadjuvant chemo/nivo with adjuvant nivo show ⬆️ DFS (HR 0.58) & ⬆️pCR in NSCLC. 23% & 35% didn’t have surgery/adjuvant nivo respectively. Debate about activity of neoadjuvant vs adjuvant vs both is ongoing. No OS. Similar Bladder cancer trials (durva/nivo/pembro) awaited.
Awesome post! LOL!
I know it looks grim right now, but I’m sure Niners fans/media feel fine because of their MVP candidate/unfairly maligned/Joe Montana 2.0 at QB.
As we get ready for 2024, let's look back at the Immunity covers of 2023! Thank you to everyone that contributed to the science & art in these beautiful, creative covers! And thanks to everyone who chose Immunity as their niche this year! 😜 What's your favorite cover?
Think this is the most interesting office I’ve visited in Silicon Valley. Love the board in the background with the names of their investments cycling through.
Fundraising News: @Playground_VC raised a new $410M fund last week, a portion of which will go towards life sciences. Managing Partner Jory Bell and Operating Partner Nate Chang describe the firm's philosophy for the sector. Full video: biotechtv.com/post/playgroun…